Hikma Eyes Return To Growth After Further Cutting Generics Forecasts

Injectables And Branded Increases Offset 18% Sales Slide For Generics Unit In First Half

Hikma has once again downgraded its expectations for its generics business in 2022 as it revealed a first-half drop of 18% in sales for the unit. However, injectables and branded increases helped to offset the decline, while the company maintained that generics growth was on the horizon in 2023.

Light at the end of the tunnel, red
Hikma sees light at the end of the tunnel for its generics business • Source: Shutterstock

Competitive pressures in the US have led Hikma to once again slash its Generics guidance for 2022, cutting its full-year sales expectations for the unit to $650m-$675m, with a core operating margin expected to come in at 15%-16%, in the face of “persistent challenges” in the US generics market.

Challenges highlighted by Brian Hoffman, president of the Generics division, included defending some of the firm’s top products in the face of increased competition – after fresh rivals to Advair Diskus (fluticasone/salmeterol) and Vascepa (icosapent ethyl) recently entered the market (Also see "Hikma Still Sees Value In Generic

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business